|1.||Dal-Pizzol, Felipe: 17 articles (10/2015 - 02/2004)|
|2.||Berk, Michael: 9 articles (12/2015 - 09/2008)|
|3.||Xia, Zhengyuan: 8 articles (01/2014 - 08/2006)|
|4.||Cheung, Po-Yin: 8 articles (04/2011 - 01/2007)|
|5.||De Flora, Silvio: 8 articles (03/2010 - 01/2002)|
|6.||Bush, Ashley I: 7 articles (12/2015 - 09/2008)|
|7.||Streck, Emilio L: 7 articles (09/2013 - 11/2007)|
|8.||Singh, Inderjit: 7 articles (11/2012 - 11/2002)|
|9.||Seguro, Antonio Carlos: 7 articles (06/2012 - 07/2004)|
|10.||Giacca, Adria: 6 articles (04/2015 - 10/2003)|
06/01/2005 - "Because N-acetyl-L-cysteine (NAC) was effective in attenuating lung reperfusion injury, its properties on aortic dysfunction were tested. "
01/01/2007 - "Numerous studies performed in recent years have shown protective effects of N-acetylcysteine (NAC) on cardiac and renal tissue damage following ischemia/reperfusion injury. "
08/01/1995 - "Protective effects of N-acetylcysteine on hypothermic ischemia-reperfusion injury of rat liver."
11/01/2005 - "N-Acetylcysteine ameliorates the late phase of liver ischaemia/reperfusion injury in the rabbit with hepatic steatosis."
05/18/2010 - "High-dose N-acetylcysteine reduced the incidence of contrast-induced nephropathy in patients with high contrast volumes and reduced reperfusion injury in animal trials. "
08/01/2009 - "To study the protective effects and mechanism of N-acetylcysteine on cardiac injury induced by ischemia/reperfusion in diabetic rats. "
08/01/2009 - "[Protective effects and mechanism of N-acetylcysteine on cardiac injury induced by ischemia/reperfusion in diabetic rats]."
01/01/2010 - "The aims of this preliminary study were to determine the alteration of serum ischemia-modified albumin (IMA) levels and to investigate whether IMA may be used as an indicator of the cardioprotective efficacy of N-acetylcysteine (NAC) in patients undergoing coronary bypass grafting (CABG). "
11/01/2013 - "We sought to evaluate the safety and efficacy of N-acetylcysteine (NAC) on ischemia and reperfusion in a pig model focusing on cardio-renal protection. "
03/01/1990 - "N-acetylcysteine (8 microM) also improved the recovery of mechanical function after ischemia both in Langendorff preparations and in working preparations. "
03/01/2005 - "In this study, the effects of an antioxidant, N-acetylcysteine (NAC), in organophosphate poisoning were investigated. "
01/01/2013 - "All of these patients received N-acetylcysteine and survived the poisoning without sequelae. "
06/01/2012 - "Priority areas include continued surveillance of the epidemiology and outcomes of poisoning, including syndromic surveillance, more rapid characterization of the human toxicity of newly introduced medicines and better clinical evidence on use of antidotes and other treatments; for example, acetylcysteine and lipid emulsion therapy."
01/01/2012 - "For patients presenting 10-24 hours after poisoning, n-acetylcysteine was more effective and the incremental cost effectiveness ratio of Sri Lankan rupees 316,182/life saved was well under the threshold. "
12/01/2010 - "The effectiveness of the antioxidant thiol, N-acetylcysteine (NAC), in enhancing methylmercury (CH3HgCl) excretion and its utility as a possible antidote in CH3HgCl poisoning has been reported. "
|4.||Acute Liver Failure (Fulminant Hepatic Failure)
05/01/2010 - "N-acetylcysteine seems to be beneficial for patients with acute liver failure caused by medications or herbal agents."
05/01/2009 - "The aim of the study was to investigate the in vitro effects of sera from children with acute liver failure (ALF) who had received N-acetylcysteine (NAC) on the metabolic and synthetic activity of cryopreserved human hepatocytes. "
01/01/2006 - "N-acetylcysteine may reduce mortality in patients with fulminant hepatic failure (Peto OR 0.26, 95% CI 0.09 to 0.94, one trial). "
05/01/2000 - "This study suggests that N-acetylcysteine administration should be considered in all patients with acute liver failure."
08/01/2013 - "[Acute liver failure -- does N-acetylcysteine improve the prognosis in children?]."
|5.||Acute Kidney Injury (Acute Renal Failure)
01/01/2014 - "Contrast-induced acute kidney injury (CI-AKI) is one of the most widely discussed and debated topic in cardiovascular medicine and N-acetylcysteine (NAC) is the most widely used pharmacological agent assessed in clinical trials for offering renal protection against CI-AKI. "
11/01/2011 - "However, three different N-acetylcysteine interventions neither significantly improved nor worsened renal function in the milder acute kidney injury model. "
11/01/2011 - "N-acetylcysteine pretreatment was effective in reducing the incidence and severity of acute kidney injury as well as in increasing survival. "
04/01/2011 - "Improved renal recovery has been shown previously with N-acetyl-l-cysteine (NAC) in various acute kidney injuries. "
02/01/2007 - "Among patients receiving N-acetylcysteine, there were trends toward reduced incidence of acute renal failure in patients with baseline Sequential Organ Failure Assessment (SOFA) score>8 (p=.12), lower SOFA scores during the first 4 days of treatment (p=.28), and reduced mortality in patients<65 yrs of age (p=.20). "
|2.||Glutathione (Reduced Glutathione)
|6.||Ascorbic Acid (Vitamin C)
|3.||Drug Therapy (Chemotherapy)